Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS2416 in Autoimmune Diseases
NCT07906145Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2026
- Primary completion
- Jun 2029
01
Overview
Phase 1, open-label trial of QLS2416 in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), primary Sjögren's syndrome and 1 more (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Safety and Tolerability of QLS2416 Injection at 24 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
QLS2416
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)primary Sjögren's syndromesystemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07906145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07906145.